Physician profile
Marc D Shields
NPI 1265435226
$1,138.81
in general payments reported to CMS, 2019-2025
12 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $25.11 · 2021: $20.57 · 2022: $231 · 2023: $187 · 2024: $190 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $237.06 | 2020-2023 | Tepezza |
| Amgen INC. | $165.73 | 2024-2025 | Tepezza |
| Abbvie INC. | $162.89 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $120.05 | 2025 | Eylea Hd |
| Mallinckrodt Hospital Products INC. | $115.27 | 2024-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $111.34 | 2019 | |
| Astellas Pharma US INC | $102.05 | 2023 | Izervay |
| Dompe US, INC. | $50.12 | 2024-2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $22.15 | 2023 | Syfovre |
| Argenx US, INC. | $20.82 | 2025 | Vyvgart Hytrulo |
| Alcon Vision LLC | $18.92 | 2025 | Precision7 |
| Johnson & Johnson Vision Care, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.